Wednesday, February 20, 2008 7:17:57 PM
http://biz.yahoo.com/pz/080220/136737.html
Sonus Pharmaceuticals Announces Fourth Quarter and Year End Results Conference Call and Presentation At WBBA Invest Northwest
Wednesday February 20, 4:00 pm ET
BOTHELL, Wash., Feb. 20, 2008 (PRIME NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (NasdaqGM:SNUS - News), an oncology drug development company, today announced that it will release financial results for the fourth quarter of fiscal 2007 ended December 31, 2007, on March 5, 2008 at 1:30 P.M. PT/4:30 P.M. ET.
Michael Martino, President and CEO, will host the call. Individuals wishing to participate in the conference call should dial 800-240-4186 or 303-262-2138 for international calls. An audio replay will be available from March 5, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Conference ID: 11109351.
Additionally, the company announced that Michael Martino, President and CEO, will present at the Washington Biotechnology and Biomedical Association (WBBA) Invest Northwest conference on Tuesday, March 18, 11:50 A.M. PT. The conference is being held in Seattle March 18-19. The Company's presentation will be broadcast live at http://ir.sonuspharma.com/events.cfm. An archive of the call will be available through the same link.
About Sonus Pharmaceuticals
Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit http://www.sonuspharma.com.
Recent ACHV News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:07:23 PM
- Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/20/2024 09:01:27 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/17/2024 06:56:31 PM
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting • GlobeNewswire Inc. • 05/17/2024 12:00:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:41 PM
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:01:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/07/2024 04:15:37 AM
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine • GlobeNewswire Inc. • 05/06/2024 03:16:04 PM
- Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/28/2024 08:01:21 PM
- Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:49:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:43:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:41:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:16:29 PM
- Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission • GlobeNewswire Inc. • 02/29/2024 01:01:00 PM
- Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 08:32:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 07:07:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 12:22:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 12:20:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 12:09:36 AM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM